Sanofi's BTK inhibitor Wayrilz has become the first drug in the class to be approved by the FDA for immune thrombocytopenia (ITP), a rare autoimmune blood disorder. Wayrilz (rilzabrutinib) has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback